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Abstract
Purpose The aim of this study was to investigate whether
performing the late cardiac 123I-metaiodobenzylguanidine
(MIBG) scan earlier than 4 h post-injection (p.i.) has relevant
impact on the late heart to mediastinum ratio (H/M ratio) in
patients with heart failure (HF).
Methods Forty-nine patients with HF (median left ventricular
ejection fraction of 31 %, 51 % ischaemic HF) referred for
cardiac 123I-MIBG scintigraphy were scanned at 15 min
(early) p.i. and at 1, 2, 3 and 4 h (late) p.i. of 123I-MIBG.
Late H/M ratios were calculated and evaluated using a linear
mixed model with the mean late H/M ratio at 4 h p.i. as a
reference. A difference in late H/M ratios of more than 0.10
between the different acquisition times in comparison with the
late H/M ratio at 4 h p.i. was considered as clinically relevant.
Results Statistically significant mean differences were ob-
served between the late H/M ratios at 1, 2 and 3 h p.i. com-
pared with the late H/M ratio at 4 h p.i. (0.09, 0.05 and 0.02,
respectively). However, the mean differences did not exceed
the cut-off value of 0.10. On an individual patient level,
compared to the late H/M ratio at 4 h p.i., the late H/M ratios
at 1, 2 and 3 h p.i. differed more than 0.10 in 24 (50 %), 9
(19 %) and 2 (4 %) patients, respectively.
Conclusion Variation in acquisition time of 123I-MIBG be-
tween 2 and 4 h p.i. does not lead to a clinically significant
change in the late H/M ratio. An earlier acquisition time seems
to be justified and may warrant a more time-efficient cardiac
123I-MIBG imaging protocol.
Keywords 123I-MIBG . Heart tomediastinum ratio . Heart
failure . Acquisition time . Planar imaging
Introduction
Heart failure (HF) is an increasing healthcare problem in the
Western world [1]. Among other features, the pathophysiol-
ogy of HF is characterized by a deregulated sympathetic
nervous system [2]. 123I-Metaiodobenzylguanidine (MIBG)
imaging is able to visualize cardiac sympathetic innervation
by providing (semi-)quantitative information on the myocar-
dial sympathetic activity [3]. Several studies have reported
that cardiac 123I-MIBG uptake provides unique information
for predicting prognosis and evaluating therapeutic effects in
patients with HF [4–7]. The semi-quantitative parameter that
is most used to analyse cardiac 123I-MIBG uptake is the
heart to mediastinum ratio (H/M ratio) of the late planar
image. The reported acquisition time for this so-called late
scan varies considerably, but it is recommended 4 h after
injection of 123I-MIBG [8]. A shorter time interval between
the injection of 123I-MIBG and the late scan reduces waiting
time and may facilitate clinical use. However, only a few
studies have investigated the impact of variation in acquisi-
tion time after 123I-MIBG administration on the late H/M
ratio [9, 10]. Therefore, the aim of this study was to
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investigate whether performing the late scan earlier than 4 h
post-injection (p.i.) has relevant impact on the late H/M ratio
in patients with HF.
Materials and methods
Patients
Fifty patients with HF from two centres (Leiden,
The Netherlands and Pisa, Italy) clinically referred for car-
diac 123I-MIBG scintigraphy between 2012 and 2015 were
included. The inclusion criteria were symptoms of HF, New
York Heart Association functional class II–IV and age be-
tween 18 and 74 years. Patients with severe shortness of
breath who were unable to lie flat for several times under
a gamma camera were excluded from this study. All patients
were treated according to the European Society of
Cardiology guidelines for the diagnosis and management
of HF and therefore received optimal pharmacological ther-
apy, revascularization and implantable defibrillator with or
without cardiac resynchronization therapy (CRT) device
when appropriate [11]. The study complied with the
Declaration of Helsinki and was approved by the Medical
Ethics Committee of the Leiden University Medical Center.
Written informed consent was obtained from all patients.
123I-MIBG data acquisition
After thyroid blockade according to the local protocol and
a resting period of 30 min, 185 MBq of 123I-MIBG
(AdreView, GE Healthcare, Princeton, NJ, USA) was ad-
ministrated as an intravenous bolus. Afterwards, 123I-MIBG
planar imaging was performed in the supine position five
times p.i.; the early acquisition was performed 15 min p.i.
and the late acquisitions were performed at 1, 2, 3 and 4 h
p.i. Planar images were acquired in the anterior view for
10 min with dual-head gamma cameras, a Siemens e.cam
(Pisa, Italy) or a Toshiba GCA-7200/PI (Leiden,
The Netherlands) and stored in a 256×256 matrix. All cam-
era heads were provided with low-energy high-resolution
collimators and the images were obtained with a 15 %
energy window centred at the 159 keV photopeak of 123I.
Planar 123I-MIBG image analysis
All planar 123I-MIBG images were transferred to the
Leiden University Medical Center for a centralized analysis.
The images were semi-quantitatively analysed by calculat-
ing the H/M ratio using dedicated post-processing software
on a Syngo-MI workstation (Siemens Medical Solutions,
Malvern, PA, USA). Manually a polygonal region of inter-
est (ROI) was drawn over the myocardium including the
left cavity and a rectangular ROI was placed upon the
upper half of the mediastinum using the following anatom-
ical landmarks: the lung apex as upper border, the upper
cardiac border and the medial contours of the lungs. The
H/M ratio was calculated by dividing the mean count den-
sity (i.e. counts/pixel) within the cardiac ROI by the mean
count density in the mediastinal ROI. The washout rate was
expressed as a percentage of decrease in myocardial counts
between early and late planar images with correction for
background and physical decay of 123I. For this calculation
the following formula was used: WRBKG corrected=[(He-
Me)-(Hl-Ml x123I decay correction)]/(He-Me) × 100 [8]. In
this formula H represents the mean count density in the
cardiac ROI and M represents the mean count density in
the mediastinal ROI in the early (e) and (l) late images.
Statistical analysis
Normally distributed variables were expressed as mean ±
standard deviation and non-normally distributed variables
as median and interquartile range (IQR). Categorical var-
iables were given as absolute values and percentages.
Patient characteristics and 123I-MIBG scintigraphy results
of subgroup analyses were compared with the indepen-
dent sample t test, the Mann-Whitney U test or the chi-
square test when appropriate. The late H/M ratios at 1, 2
and 3 h p.i. were compared with the late H/M ratio at 4 h
p.i. with a linear mixed model with a given fixed factor
time. A mean difference in late H/M ratio of more than
0.10 between the (mean) different H/M ratios at 1, 2 and
3 h p.i. and the (mean) late H/M at 4 h p.i. was considered
clinically relevant. This was assessed by evaluating
whether the 95 % confidence intervals (CI) for the real
differences in means of the late H/M ratios at 1, 2 and 3 h
p.i., respectively, compared with the late H/M ratio at 4 h
p.i. included the value 0.1. In the subgroup analysis, the
influence of left ventricular ejection fraction on the differ-
ences in late H/M ratios between the ischaemic and non-
ischaemic HF groups at 1, 3 and 4 h p.i. was assessed by
performing multivariate logistic regression analyses in-
cluding H/M ratio and left ventricular ejection fraction.
The washout rates between 15 min and 1, 2 and 3 h p.i.
were compared with the washout rate between 15 min and
4 h p.i. with a linear mixed model with a given fixed
factor time. A paired t test power analysis demonstrated
that a sample size of 49 patients achieved 90 % power to
reject the null hypothesis that the test and standard are
equivalent, thereby assuming an absolute difference of
more than 0.10 with an estimated standard deviation of
0.20 with a significance level (alpha) of 0.01670. A two-
sided p value <0.05 was considered statistically signifi-
cant. All analyses were performed with SPSS software
(Version 22.0, SPSS IBM Corp., Armonk, NY, USA).
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Results
Patients
The study population comprised 49 patients with HF, because
1 patient withdrew his informed consent after the examina-
tion. The patient characteristics of the study population are
depicted in Table 1. Seventy-six per cent (37/49) of the total
study population was male with a mean age of 64±9 years.
The aetiology of HF was ischaemic in 51 % (25/49) of the
patients. Patients with ischaemic HF had a statistically signif-
icantly lower left ventricular ejection fraction compared with
patients with non-ischaemic HF, 28 % (IQR 23–35) versus
33 % (IQR 29–40) (p=0.04), respectively, and antiplatelet or
oral anticoagulant therapy was more frequent at 96 % (24/25)
versus 75 % (18/24) (p=0.04), respectively.
Table 1 Characteristics of the study population (n=49)








Age (years) 64±9 66±9 62±8 0.08
Sex (male) 37 (76 %) 21 (84 %) 16 (67 %) 0.16
Height (cm) 176±9 175±8 176±10 0.73
Weight (kg) 85±14 84±13 87±14 0.36
Cardiovascular risk factors
Diabetes mellitusa 8 (16 %) 4 (16 %) 4 (17 %) 0.95
Obesity, BMI≥30 (kg/m2) 7 (14 %) 2 (8 %) 5 (21 %) 0.20
Family history of CVDb 19 (39 %) 9 (36 %) 10 (42 %) 0.68
Hypercholesterolaemiac 27 (55 %) 16 (64 %) 11 (46 %) 0.20
Hypertensiond 30 (61 %) 13 (52 %) 17 (71 %) 0.18
Current smoker 8 (16 %) 4 (16 %) 4 (17 %) 0.95
Ejection fraction (%) 31 (IQR 25-38) 28 (IQR 23-35) 33 (IQR 29-40) 0.04
CRT-D/ICD therapy 31 (63 %) 17 (68 %) 14 (58 %) 0.48
Medication
ACE/AT-II inhibitor 45 (92 %) 23 (92 %) 22 (92 %) 0.97
Beta blocker 39 (80 %) 20 (80 %) 19 (79 %) 0.94
Calcium antagonist 3 (6 %) 2 (8 %) 1 (4 %) 0.58
Lipid-lowering agent 35 (71 %) 20 (80 %) 15 (63 %) 0.18
Antiplatelet/OAC therapy 42 (86 %) 24 (96 %) 18 (75 %) 0.04
Diuretics 38 (78 %) 22 (88 %) 16 (67 %) 0.07
Oral antidiabetics 8 (16 %) 4 (16 %) 4 (17 %) 0.95
Insulin 3 (6 %) 1 (4 %) 2 (8 %) 0.53
Nitrates 3 (6 %) 3 (12 %) 0 (0 %) 0.08
NYHA class 0.28
I 11 (22.45 %) 7 (28.0 %) 4 (16.7 %)
II 27 (55.1 %) 11 (44.0 %) 16 (66.6 %)
III 11 (22.45 %) 7 (28.0 %) 4 (16.7 %)
NT-proBNP (pg/l) 771 (IQR 428–1,264) 900 (IQR 451–1,487) 716 (IQR 331–1,244) 0.34
ACE angiotensin-converting enzyme inhibitor, AT-II angiotensin II, BMI body mass index, CRT-D cardiac resynchronization therapy defibrillator, CVD
cardiovascular disease,HF heart failure, ICD implantable cardioverter defibrillator, IQR interquartile range,NT-proBNPN-terminal pro-brain natriuretic
peptide, NYHA New York Heart Association, OAC oral anticoagulant
a Self-reported history of diabetes mellitus and/or treatment with antidiabetics
b Presence of coronary artery disease in first-degree family members at age <55 years in men and <65 years in women
c Self-reported history of hypercholesterolaemia and/or treatment with lipid-lowering drugs
d Self-reported history of hypertension and/or use of antihypertensivemedication or a systolic blood pressure ≥140mmHg and/or diastolic blood pressure
≥90 mmHg
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Planar 123I-MIBG image analysis
The results of the planar 123I-MIBG image analysis are shown
in Table 2. Of the 49 patients, 1 patient did not have an acqui-
sition 4 h p.i. In the total study population the late H/M ratio
was 1.60±0.18 at 1 h, 1.56±0.19 at 2 h p.i. and 1.53±0.19 at
3 h p.i. and differed all significantly from the late H/M ratio of
1.52±0.20 at 4 h p.i. (p <0.001, p<0.001 and p=0.02, respec-
tively). However, none of the mean differences between the
late H/M ratios at 1, 2 and 3 h p.i. exceeded the predefined
clinically relevant 0.10 difference with the late H/M ratio at
4 h p.i. (Fig. 1a). An example of a patient with only small
differences between the late H/M ratios at 1, 2 and 3 h p.i.
compared with the late H/M ratio at 4 h p.i. is depicted in
Fig. 2. On an individual patient level, compared to the late
H/M ratio at 4 h p.i., the late H/M ratios at 1, 2 and 3 h p.i.
differed more than 0.10 in 24 (50 %), 9 (19 %) and 2 (4 %)
patients, respectively (Fig. 1b).
The H/M ratios of the early scan and the late scan
performed at 1, 3 and 4 h p.i. were significantly higher
in the non-ischaemic HF group in comparison with the
ischaemic HF group (p=0.03, p=0.02, p=0.03 and p=
0.03, respectively). When corrected for the left ventricular
ejection fraction there was no independent association be-
tween the late H/M ratio at 1, 3 and 4 h p.i. and type of
HF [odds ratio (OR) 0.09 (95 % CI 0.006–0.18), p=0.07;
OR 0.07 (95 % CI −0.027 to 0.17), p=0.16 and OR 0.06
(95 %CI −0.03 to 0.16), p=0.16, respectively]. Figure 3
shows the mean differences in late H/M ratios at 1, 2 and
3 h p.i. compared with the late H/M ratio at 4 h p.i. in
both subgroups. Compared to the late H/M ratio at 4 h
p.i., the mean late H/M ratios at 1 and 2 h p.i. were
statistically significantly different in the ischaemic HF
group (both p<0.001) as well as in the non-ischaemic
HF group (p<0.001 and p=0.005, respectively). In the
non-ischaemic HF group only the mean late H/M ratio
at 1 h p.i. exceeded the predefined clinically relevant
0.10 difference with the late H/M ratio 4 h p.i.
The mean washout rate between the early scan and the late
scans at 1, 2, 3 and 4 h p.i. increased from 11±12 % to 21±
16 %, 29±17 % and 34±17 %. The mean washout rates be-
tween the early scan and the late scans at 1, 2 and 3 h p.i.
differed all statistically significantly from the washout rate
between the early and 4-h p.i. scan (all p <0.001). There was
no statistically significant difference between the washout rates
in the ischaemic HF and the non-ischaemic HF subgroups.
Discussion
The present study evaluated the impact of variations in ac-
quisition time of planar 123I-MIBG scintigraphy on the late
H/M ratio in patients with HF. There were statistically sig-
nificant differences between the late H/M ratios at 1, 2 and
3 h p.i. compared with the late H/M ratio at 4 h p.i.
However, compared with the late H/M ratio at 4 h p.i., the
Table 2 123I-MIBG scintigraphy
results MIBG scintigraphy Total group (n=49) Patient subgroup
Ischaemic HF (n=25) Non-ischaemic HF (n=24) p value
Actual acquisition time after injection (min)
Early scan 15 (IQR 13–19) 15 (IQR 13–22) 14 (IQR 12–17) 0.08
Late scan 1 h 66 (IQR 62–71) 69 (IQR 64–73) 64 (IQR 59–67) 0.01
Late scan 2 h 118 (IQR 115–123) 119 (IQR 116–123) 117 (IQR 114–122) 0.26
Late scan 3 h 178 (IQR 176–182) 179 (IQR 176–182) 177 (IQR 174–181) 0.17
Late scan 4 h 239 (IQR 236–245) 238 (IQR 236–246) 240 (IQR 236–245) 0.70
H/M ratio
Early scan 1.60±0.15 1.55±0.15 1.64±0.14 0.03
Late scan 1 h 1.60±0.18 1.54±0.16 1.66±0.18 0.02
Late scan 2 h 1.56±0.19 1.51±0.17 1.61±0.21 0.09
Late scan 3 h 1.53±0.19 1.47±0.16 1.59±0.20 0.03
Late scan 4 h 1.52±0.20 1.46±0.17 1.58±0.21 0.03
Washout rate (%)
Late scan 1 h 11±12 13±12 9±11 0.23
Late scan 2 h 21±16 21±16 21±16 0.96
Late scan 3 h 29±17 32±17 26±17 0.29
Late scan 4 h 34±17 36±17 33±17 0.50
HF heart failure, IQR interquartile range
Eur J Nucl Med Mol Imaging (2016) 43:326–332 329
late H/M ratios at 1, 2 and 3 h p.i. did not exceed the
predefined clinically relevant cut-off difference of 0.10.
The late H/M ratio is the most frequently used param-
eter to semi-quantitatively analyse the cardiac 123I-MIBG
uptake in patients with HF [12]. The Cardiovascular
Committee of the European Association of Nuclear
Medicine and the European Council of Nuclear
Cardiology recommend calculating the late H/M ratio
from planar images at 4 h after receiving 123I-MIBG [8].
This recommendation is based on several studies [13–17].
First, Nakajo et al. investigated the appropriate time for
cardiac radioiodine-labelled MIBG imaging [14]. This
study demonstrated in rats that the accumulation of cardi-
ac 131I-MIBG in adrenergic nerves reached a maximum
plateau at 4 h p.i., while the accumulation of the tracer
in other compartments rapidly decreased in a period of 6 h
p.i. Second, the mechanism of myocardial uptake of 123I-
MIBG in the presynaptic sympathetic nerve endings was
elucidated by DeGrado et al. [15]. This group demonstrat-
ed that 123I-MIBG uptake was mainly between 1 and
7 min p.i. and depended primarily on both uptake-1 (the
neuronal pathway via the norepinephrine transporter) as
well as on uptake-2 (the extraneuronal pathway) activity.
The clearance half-time of neuronal 123I-MIBG uptake
(via uptake-1) was 112 min, in contrast to the much lower
clearance half-time of extraneuronal 123I-MIBG uptake
(uptake-2) of 22 min. Finally, Sisson et al. demonstrated
that 123I-MIBG patterns in the heart were consistent with
the concept that 123I-MIBG resides mostly in adrenergic
neurons, mainly via the uptake-1 mechanism [16, 17].
This supports the hypothesis that the late H/M ratio at
4 h p.i. mainly represents the uptake, storage and release
of 123I-MIBG in the myocardial vesicles at the nerve ter-
minals, while accumulation in extraneuronal compart-
ments is relatively low.
In the present study only small differences (≤0.10) were
observed between the late H/M ratios at 1, 2 and 3 h p.i.
compared with the commonly used late H/M ratio at 4 h p.i.
Subgroup analysis between patients with ischaemic and non-
ischaemic HF showed similar results. At the patient level, a
high percentage of patients (50 %) exceeded a difference of
0.10 between the late H/M ratio at 1 h p.i. compared to the
late H/M ratio at 4 h p.i. In contrast, between the late H/M
ratio at 2 h p.i. and the late H/M ratio at 4 h p.i. the per-
centage of patients who exceeded a difference of 0.10 was
much lower (19 %). In comparison with the late H/M ratios
at 3 and 4 h p.i. only 4 % of the patients had a difference of
more than 0.10. These results are in line with a previous
investigation by Kline et al., who demonstrated a small dif-
ference in late heart to lung ratio in four healthy subjects
between 1 and 2 h after administration of 74 MBq 123I-
MIBG of approximately 1.3 versus 1.44 [3]. More recently,
Fig. 1 Mean differences (a) and absolute differences (b) of each individual
patient in the H/M ratios at 1, 2 and 3 h p.i. in comparison with H/M ratio
at 4 h p.i. The mean difference with 95 % CI of H/M ratios of late 123I-
MIBG images with acquisition at 1, 2 and 3 h p.i. in comparison with the
H/M ratio of the late 123I-MIBG image at 4 h p.i. analysed with a linear
mixed model (a). Each dot represents an absolute difference of each
individual patient in the late H/M ratios at 1, 2 and 3 h p.i. compared
with the late H/M ratio at 4 h p.i. (b). Amean difference in H/M ratio ofmore
than 0.10 between the different acquisition times in comparison with the late
H/M ratio at 4 h p.i. was considered clinically relevant
Fig. 2 Example of a patient with
ischaemic HF and planar
acquisitions 1, 2, 3 and 4 h p.i.,
respectively
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Giorgetti et al. reported the mean H/M ratios at different
acquisition times in six pigs after administration of 54±
14 MBq 123I-MIBG using a cadmium zinc telluride camera.
The mean H/M values±SD, at 125 min, extrapolated to 176
and 240 min, were 4.33±1.23 %, 3.95±1.46 % and 3.63 ±
1.64 %, respectively. In addition, Okuda et al. demonstrated
in 96 patients that the mean count density in the cardiac ROI
and the mediastinum ROI at 3 h were highly correlated with
the mean count density in the cardiac ROI and the medias-
tinum ROI at 4 h (r=0.98, p<0.0001 and r=0.89,
p<0.0001) as well as the fact that there was only a small
mean difference of 0.02 between the late H/M ratios at 3 and
4 h p.i. (1.88±0.56 and 1.86±0.57, respectively) [9]. Slow
efflux of 123I-MIBG from the neuronal compartments can
probably explain the small differences between late H/M
ratios in the latter and the present study [13, 18].
The present results show that, at a group as well as at
an individual patient level, the change in the late H/M
ratios between 2 and 4 h p.i. is limited and probably
not clinically relevant. Since the late H/M ratio has been
proven to provide important information in predicting
prognosis in HF patients [4], our results may have clinical
implications by allowing a more flexible and/or shorter
interval between the injection of 123I-MIBG and the acqui-
sition time of the late scan for the determination of the
late H/M ratio, especially in patients with HF.
With a shorter interval between the injection of 123I-
MIBG and the Blate^ scan the washout rate will change.
Previous studies have shown that the instant myocardial
uptake of 123I-MIBG uptake normalized for blood pool
activity is close to zero after 3 h [10]. Evaluating the
washout rate at least 3 h after radiotracer injection is
therefore recommended. However, Arimoto et al. demon-
strated in 42 patients with HF a good correlation of the
early washout rate between 5 and 15 min and the washout
rate between 15 min and 3 h (r=0.606, p<0.0001) [19].
Moreover, the early washout rate provided prognostic in-
formation as well. In addition, Henderson et al. demon-
strated that a washout rate recorded between 15 and
85 min showed a significant difference in 16 patients with
non-ischaemic cardiomyopathy compared with 14 healthy
volunteers: 28±12 % and 6±8 %, respectively (p<0.001)
[20]. Additional imaging was performed in a subset of
patients (n=8) at 4 h p.i. and 123I-MIBG retention ap-
peared to be lower and showed greater disparity in the
washout rate. In the present study, myocardial 123I-
MIBG washout increased over time from 11±12 % at
1 h p.i. to 34±17 % at 4 h p.i. The mean washout rates
between the early scan and the late scans at 1, 2 and 3 h
p.i. differed all statistically significantly from the washout
rate between the early and 4-h p.i. scan (all p <0.001).
Limitations
It should be addressed that although myocardial washout rates
were corrected for 123I decay and mediastinal background, the
myocardial washout rate can still be influenced by 123I-MIBG
washout in surrounding lung and liver tissues [21]. Moreover,
more research is needed before implementing the acquisition
time at 2 h to avoid misclassification since the difference be-
tween the late H/M ratio at 2 h p.i. in comparison with 4 h p.i.
at the patient level was not non-negligible.
Conclusion
Variation in acquisition time of 123I-MIBG between 2 and 4 h
p.i. does not lead to a clinically significant change in the late
H/M ratio. With the knowledge that the late H/M ratio is the
best validated and most used prognostic parameter for cardiac
sympathetic innervation in patients with HF, an earlier acqui-
sition time seems to be justified and may warrant a more time-
efficient cardiac 123I-MIBG imaging protocol.





























Fig. 3 Mean differences of the late H/M ratios at 1, 2 and 3 h p.i. in
comparison with the late H/M ratio at 4 h p.i. in the ischaemic HF and
non-ischaemic HF subgroups. Mean difference with 95 % CI of H/M
ratio of late 123I-MIBG images at 1, 2 and 3 h p.i. in comparison with
H/M ratio of late 123I-MIBG image at 4 h p.i. analysedwith a linear mixed
model in the ischaemic HF (blue) and non-ischaemic HF (red) subgroups.
A difference in H/M ratio of more than 0.10 between the different acqui-
sition times in comparison with the late H/M ratio at 4 h was considered
clinically relevant
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